Tests whether rivaroxaban can be taken only when atrial fibrillation returns after ablation
Compares continuous rivaroxaban with taking it only after atrial fibrillation returns, in people after ablation.
Plain-language title generated from the registry record
Registry title: Pill-in-the-POCKET Oral Anticoagulation Strategy After AF Catheter Ablation
Key facts
- Where
- Seoul, South KoreaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 19 and 89 years old?
Source: NCT06216769, who can take part
Where in South Korea
- Seoul National University HospitalSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Seoul National University Hospital
- Trial code
- NCT06216769
- Record updated
- 4 May 2026
- Original description
The clinical benefit of pill-in-the-POCKET anticoagulation after atrial fibrillation catheter ablation remains uncertain. We aimed to evaluate the clinical benefit and safety of pill-in-the-POCKET anticoagulation after atrial fibrillation catheter ablation by randomizing into two groups: non-interrupted anticoagulation after the procedure and anticoagulation based on atrial fibrillation recurrence confirmed by implantable loop recorders.Read full original descriptionShow less
Comparison Between Continuous Oral Anticoagulation Versus Pill-in-the-POCKET Oral AntiCoagulation Strategy Guided by Continuous Rhythm Monitoring Using Implantable Loop Recorder After Atrial Fibrillation Catheter Ablation
The clinical benefit of pill-in-the-POCKET anticoagulation after atrial fibrillation catheter ablation remains uncertain. We aimed to evaluate the clinical benefit and safety of pill-in-the-POCKET anticoagulation after atrial fibrillation catheter ablation by randomizing into two groups: non-interrupted anticoagulation after the procedure and anticoagulation based on atrial fibrillation recurrence confirmed by implantable loop recorders.
Inclusion: Patients who are scheduled to undergo atrial fibrillation catheter ablation due to atrial fibrillation refractory to antiarrhythmic drug treatment; Patients with non-gender CHA2DS2-VASc score 1-4; Patients who are taking direct oral anticoagulants (rivaroxaban, dabigatran, apixaban, edoxaban) and further plan taking them life-long to prevent stroke caused by atrial fibrillation; Patients aged 19-89 (inclusive) who voluntarily sign the informed consent form.
Exclusion: The patient has previously implanted cardiac implantable electronic devices or ILR; Patients with a stroke/transient ischemic attack history; Patients with underlying diseases and bleeding findings contraindicated to anticoagulation (e.g., coagulation disorders, bleeding conditions, significant gastrointestinal bleeding within 6 months of enrollment, history of intracranial/intraocular/nontraumatic bleeding, thrombolysis within 48 hours of study enrollment); Patients who are hemodynamically unstable at the time of study enrollment: cardiogenic shock, treatment-unresponsive ventricular arrhythmia, or congestive heart failure (NYHA class IV) at the time of randomization; The patient has severe liver disease (variceal bleeding, ascites, hepatic encephalopathy, or jaundice); The patient has a contraindication to the implantation of an implantable loop recorder (ILR) (such as limited immunocompetence or a wound-healing disorder); The patient has severe valvular disease (valvular prosthesis, mitral valve repair; rheumatic mitral stenosis is excluded irrespective of the severity of the disease); The patient has a non-arrhythmic condition necessitating long-term oral anticoagulation; The patient is deemed high risk for non-cardioembolic stroke (i.e. significant carotid artery disease); Known or suspected malignancy with a history of chemotherapy within 1 year; Patients with a history of left atrial appendage occlusion or left atrial appendage closure; Patients with underlying severe anemia (hemoglobin <8 g/dL at baseline) or a transfusion history within four weeks before visit 1; Patients with underlying severe thrombocytopenia (platelet count <50,000/mm3); The patient is under dialysis or chronic renal failure (creatinine clearance <15ml/min); Pregnancy, breastfeeding, or women of childbearing age who refuse to use a highly effective and medically acceptable form of contraception throughout the study. *; Medically acceptable contraceptives include condoms, injectable or implantable contraceptives, intrauterine devices, and oral contraceptives; Patients who are contraindicated to anticoagulants other than those listed above; Hypertrophic cardiomyopathy; Patients who are taking warfarin or coumadin; Patients who are taking dual antiplatelet agents; The patient is participating in another randomized clinical trial and is under follow-up observation.